Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues.
In this report we describe various aspects of tumor and normal tissue radiosensitization by nicotinamide. The LD50 for a single injection of nicotinamide in C3H mice was found to be 2050 mg/kg. When a large nonlethal dose (1000 mg/kg) was injected into tumor-bearing mice, peak plasma and tumor levels were reached 30-60 min after injection and decayed with a half-life of about 3 h. This dose of nicotinamide enhanced radiation-induced cell killing in three different tumor models (EMT6, Lewis Lung, and RIF-1) when injected at least 1 h before irradiation and produced enhancement ratios (ERs) of between 1.2 and 1.7. The ER in the EMT6 tumor was dependent on the dose of nicotinamide injected, but even at doses as low as 25% of the LD50 value an ER greater than 1.5 could still be observed. In two normal tissue assays (jejunum crypt cell survival and mean skin reaction) ERs of less than 1.2 were obtained. These results, and the fact that high levels can be tolerated in humans, suggest that nicotinamide, or a structurally related compound, could be a likely candidate for development in clinical trials.
D000818:Animals; D002470:Cell Survival / Q000528:radiation effects; D004307:Dose-Response Relationship, Radiation; D005260:Female; D007583:Jejunum / Q000166:cytology; D007928:Lethal Dose 50; D051379:Mice; D008809:Mice, Inbred C3H; D009374:Neoplasms, Experimental / Q000532:radiotherapy*; D009536:Niacinamide / Q000494:pharmacology* / Q000633:toxicity; D011838:Radiation-Sensitizing Agents; D013997:Time Factors
D011838:Radiation-Sensitizing Agents; D009536:Niacinamide